A clinical trial known as the ROADS trial, led by MD Anderson Cancer Center and presented at the 2026 American Society of Clinical Oncology meeting, has found that placing radioactive collagen tiles into the brain cavity at the time of tumor removal dramatically reduces recurrence and extends survival for patients with brain cancer. This development offers hope that brain cancers could be successfully treated as more advancements are made over the coming years.
The study's findings suggest that the localized delivery of radiation via collagen tiles can target residual cancer cells that may remain after surgery, potentially preventing regrowth. This approach could change the standard of care for brain cancer patients, who currently face high rates of recurrence despite aggressive treatment.
The implications for patients are significant: reduced recurrence rates could mean fewer additional surgeries, less need for systemic therapies with harsh side effects, and overall improved quality of life. For the medical community, the ROADS trial underscores the potential of combining surgical resection with targeted intraoperative radiotherapy.
Other companies are also making progress in brain cancer treatments. For instance, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is advancing its own therapies, highlighting a broader push toward more effective treatments for these devastating diseases.
While the ROADS trial is a critical step forward, further research and larger studies will be needed to confirm these findings and determine the long-term benefits and risks. Nonetheless, the results provide a promising avenue for improving outcomes in brain cancer patients, a population that has historically had limited options.
